Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Genome-wide association study of panic disorder reveals genetic overlap with neuroticism and depression.

Forstner AJ, Awasthi S, Wolf C, Maron E, Erhardt A, Czamara D, Eriksson E, Lavebratt C, Allgulander C, Friedrich N, Becker J, Hecker J, Rambau S, Conrad R, Geiser F, McMahon FJ, Moebus S, Hess T, Buerfent BC, Hoffmann P, Herms S, Heilmann-Heimbach S, Kockum I, Olsson T, Alfredsson L, Weber H, Alpers GW, Arolt V, Fehm L, Fydrich T, Gerlach AL, Hamm A, Kircher T, Pané-Farré CA, Pauli P, Rief W, Ströhle A, Plag J, Lang T, Wittchen HU, Mattheisen M, Meier S, Metspalu A, Domschke K, Reif A, Hovatta I, Lindefors N, Andersson E, Schalling M, Mbarek H, Milaneschi Y, de Geus EJC, Boomsma DI, Penninx BWJH, Thorgeirsson TE, Steinberg S, Stefansson K, Stefansson H, Müller-Myhsok B, Hansen TF, Børglum AD, Werge T, Mortensen PB, Nordentoft M, Hougaard DM, Hultman CM, Sullivan PF, Nöthen MM, Woldbye DPD, Mors O, Binder EB, Rück C, Ripke S, Deckert J, Schumacher J.

Mol Psychiatry. 2019 Nov 11. doi: 10.1038/s41380-019-0590-2. [Epub ahead of print]

PMID:
31712720
2.

Correction to: Imaging and Genetic Approaches to Inform Biomarkers for Anxiety Disorders, Obsessive-Compulsive Disorders, and PSTD.

Maron E, Lan CC, Nutt D.

Curr Top Behav Neurosci. 2018;40:437. doi: 10.1007/7854_2018_64.

PMID:
30488349
3.

Imaging and Genetic Approaches to Inform Biomarkers for Anxiety Disorders, Obsessive-Compulsive Disorders, and PSTD.

Maron E, Lan CC, Nutt D.

Curr Top Behav Neurosci. 2018;40:219-292. doi: 10.1007/7854_2018_49. Erratum in: Curr Top Behav Neurosci. 2018;40:437.

PMID:
29796838
4.

Personality traits and escitalopram treatment outcome in major depression.

Aluoja A, Tõru I, Raag M, Eller T, Võhma Ü, Maron E.

Nord J Psychiatry. 2018 Jul;72(5):354-360. doi: 10.1080/08039488.2018.1465590. Epub 2018 Apr 24.

PMID:
29688152
5.

Biological markers of generalized anxiety disorder.

Maron E, Nutt D.

Dialogues Clin Neurosci. 2017 Jun;19(2):147-158. Review.

6.

Association between personality traits and Escitalopram treatment efficacy in panic disorder.

Võhma Ü, Raag M, Tõru I, Aluoja A, Maron E.

Nord J Psychiatry. 2017 Aug;71(6):433-440. doi: 10.1080/08039488.2017.1316772. Epub 2017 May 4.

PMID:
28472591
7.

The course of cognitive functioning after first-episode of psychosis: A six month follow-up study.

Haring L, Mõttus R, Kajalaid K, Koch K, Uppin K, Maron E, Vasar E.

Schizophr Res. 2017 Apr;182:31-41. doi: 10.1016/j.schres.2016.10.017. Epub 2016 Oct 13.

PMID:
27746055
8.

Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression.

Pettai K, Milani L, Tammiste A, Võsa U, Kolde R, Eller T, Nutt D, Metspalu A, Maron E.

Eur Neuropsychopharmacol. 2016 Sep;26(9):1475-1483. doi: 10.1016/j.euroneuro.2016.06.007. Epub 2016 Jul 22.

PMID:
27461515
9.

Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, Cinosi E, Davies S, Domschke K, Fineberg N, Grünblatt E, Jarema M, Kim YK, Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Ströhle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P.

World J Biol Psychiatry. 2017 Apr;18(3):162-214. doi: 10.1080/15622975.2016.1190867. Epub 2016 Jul 15. Review.

10.

Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics.

Bandelow B, Baldwin D, Abelli M, Altamura C, Dell'Osso B, Domschke K, Fineberg NA, Grünblatt E, Jarema M, Maron E, Nutt D, Pini S, Vaghi MM, Wichniak A, Zai G, Riederer P.

World J Biol Psychiatry. 2016 Aug;17(5):321-65. doi: 10.1080/15622975.2016.1181783. Epub 2016 Jul 12.

PMID:
27403679
11.

A pilot study of the effect of short-term escitalopram treatment on brain metabolites and gamma-oscillations in healthy subjects.

Maron E, Near J, Wallis G, Stokes M, Matthews PM, Nutt DJ.

J Psychopharmacol. 2016 Jun;30(6):579-80. doi: 10.1177/0269881116636108. No abstract available.

12.

Effect of short-term escitalopram treatment on neural activation during emotional processing.

Maron E, Wall M, Norbury R, Godlewska B, Terbeck S, Cowen P, Matthews P, Nutt DJ.

J Psychopharmacol. 2016 Jan;30(1):33-9. doi: 10.1177/0269881115620462. Epub 2015 Dec 8.

PMID:
26645207
13.

Biological predictors of pharmacological therapy in anxiety disorders.

Maron E, Nutt D.

Dialogues Clin Neurosci. 2015 Sep;17(3):305-17. Review.

14.

Polymorphisms of IKBKE gene are associated with major depressive disorder and panic disorder.

Traks T, Koido K, Balõtšev R, Eller T, Kõks S, Maron E, Tõru I, Shlik J, Vasar E, Vasar V.

Brain Behav. 2015 Apr;5(4):e00314. doi: 10.1002/brb3.314. Epub 2015 Feb 13.

15.

Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sample.

Haring L, Mõttus R, Jaanson P, Pilli R, Mägi K, Maron E.

Ann Gen Psychiatry. 2013 Sep 11;12(1):28. doi: 10.1186/1744-859X-12-28.

16.

Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression.

Tammiste A, Jiang T, Fischer K, Mägi R, Krjutškov K, Pettai K, Esko T, Li Y, Tansey KE, Carroll LS, Uher R, McGuffin P, Võsa U, Tšernikova N, Saria A, Ng PC, Eller T, Vasar V, Nutt DJ, Maron E, Wang J, Metspalu A.

J Psychopharmacol. 2013 Oct;27(10):915-20. doi: 10.1177/0269881113499829. Epub 2013 Aug 7.

PMID:
23926243
17.

Unedited in vivo detection and quantification of γ-aminobutyric acid in the occipital cortex using short-TE MRS at 3 T.

Near J, Andersson J, Maron E, Mekle R, Gruetter R, Cowen P, Jezzard P.

NMR Biomed. 2013 Nov;26(11):1353-62. doi: 10.1002/nbm.2960. Epub 2013 May 22.

PMID:
23696182
18.

Genetic factors in anxiety disorders.

Domschke K, Maron E.

Mod Trends Pharmacopsychiatry. 2013;29:24-46. doi: 10.1159/000351932. Epub 2013 Sep 20. Review.

PMID:
25225016
19.

The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.

Tõru I, Maron E, Raag M, Vasar V, Nutt DJ, Shlik J.

Eur Neuropsychopharmacol. 2013 Jul;23(7):645-52. doi: 10.1016/j.euroneuro.2012.08.011. Epub 2012 Aug 29.

PMID:
22939006
20.

Neuroimaging of serotonin system in anxiety disorders.

Maron E, Nutt D, Shlik J.

Curr Pharm Des. 2012;18(35):5699-708. Review.

PMID:
22632475

Supplemental Content

Loading ...
Support Center